News

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution), commercialised as EvoTears in Europe, is the first prescription eye drop that targets tear evaporation.

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution) is the first prescription eye drop that targets tear evaporation.

According researchers at the University of Gothenburg, for patients who recently received a diagnosis, discovery of glaucoma could mean they start treatment with daily eye drops that lower the pressure in the eye and slow down the damage to the optic nerve.

Targeting the interleukin-11 receptor, LASN01 is a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).

The Ophthalmic World Leaders (OWL) Leadership Summit, scheduled for September 21 and 22, 2023, in Austin, Texas, will feature a lineup of prominent speakers and engaging discussions on a wide range of leadership topics and industry insights.

Debbie Allen, an award-winning actress, dancer, choreographer, singer-songwriter, director and producer is teaming up with Prevent Blindness and Regeneron for the Gr8 Eye Movement, an awareness campaign that aims to educate and encourage those who are at risk of certain retinal diseases to prioritize their eye health.

In this key role, Weil will lead the organization to commercial readiness from designing launch strategies for the US and globally.

According to the company, OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which causes one of the most severe early-onset retinal dystrophies.

At this year's ESCRS meeting, we visited the Oertli Instruments booth, where co-CEO and co-owner Thomas Bosshard highlighted the company's 3-platform approach.

Ocular Therapeutic, Rezolute, and Opthea will all present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City in September.

The study examines the effectiveness of PL9643 for the treatment of patients with dry eye disease.

At the 2023 European Society Of Cataract & Refractive Surgeons (ESCRS) meeting in Vienna, Krysten Williams, head of marketing and education at Heidelberg Engineering, spoke to our team about the newest imaging advancements in the clinic and the operating room.

According to the company, it has 9 presentations at the annual congress of the European Society of Cataract and Refractive Surgeons being held in Vienna. AVG also is a sponsor of the International Society of Presbyopia.

The company has 9 presentations at the annual congress of the European Society of Cataract and Refractive Surgeons being held in Vienna. AVG also is a sponsor of the International Society of Presbyopia.

According to the companies, the collaboration has the potential to benefit patients who have suffered from specific, chronic ocular diseases.

The trial is for the MINIject MIGS device for patients with primary open-angle glaucoma.

Jorge Alio, MD, PhD, FEBOpthhal spoke with our team about his Binkhorst Medal lecture topic, the future of cataract and refractive surgery, while at the 2023 ESCRS meeting in Vienna, Austria.

The company is expanding its patent portfolio to 10 granted patents and 32 pending patent applications.

The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.

Euan Thomson, the President of Ophthalmic Devices, Carl Zeiss Meditec spoke with our team about integrated workflow solutions and how they can benefit cataract procedures while at the 2023 ESCRS meeting in Vienna, Austria.

OWL's ESCRS 2023 event on Sunday, September 10, at 7 pm, promises an evening of visionary leadership and collaboration in ophthalmic innovation.

The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.

DMEI is 1 of only 17 centers in the US certified to provide this specialized treatment. Previously, patients in the region who qualified for LUXTURNA would have had to travel to other states to receive treatment.

A new survey shows that 95% of adults at risk for certain retinal diseases know a little or nothing about them. Allen hopes her story will help raise awareness and encourage those at risk to regularly prioritize their eye health.

Jeff Todd talks about the campaign and partnering with actress Debbie Allen to help gain awareness on eye health.

The system is a next generation aqueous shunt therapy for patients with moderate to severe glaucoma.